Vitamin B12 is a water-soluble vitamin, meaning that your body excretes what you dont need in your urine, including any excess consumed via supplements or food
Exploring these options can provide diverse ways of achieving and maintaining healthy, glowing skin, allowing you to find a routine that best fits your lifestyle and skincare needs
If you feel Wegovy isnt working for you, there are several other options available that may be more suitable
In October 2024, Lilly announced a partnership with Health Innovation Manchester and The University of Manchester to initiate a five-year real-world study, SURMOUNT-REAL UK [9]
GET STARTED Injectable Testosterone + hCG / GONADORELIN 1 Month Injectable Kit Dosed at 200mg weekly INCLUDES SUPPLIES $ 120/month *To ensure consistent treatment and prevent gaps or monthly drop-off issues, we do not offer monthly prescriptions or subscription plans

Alternative Approaches Being Researched: Other Companies Oral GLP-1 Programs: Several pharmaceutical and biotech companies are developing oral GLP-1 or dual agonist medications: Pfizer: Developing oral GLP-1 receptor agonist (danuglipron) Different molecule than semaglutide or tirzepatide Phase 2 trials showed promise but also significant GI side effects Still years from potential approval Novo Nordisk: Researching higher-dose oral semaglutide formulations Exploring oral versions of other GLP-1 medications in pipeline Owns SNAC technology, giving them advantage Veru Inc.: Developing oral GLP-1 using different technology Early-stage research At least 5-7 years from approval if successful Structure Therapeutics: Oral GLP-1 receptor agonist in development Early clinical trials Results not yet published Realistic Expectations: Whats Likely by 2030: Improved oral semaglutide formulations (higher doses, better absorption) Possibly oral tirzepatide if development accelerates Other oral GLP-1 medications from competing companies Better absorption technologies Whats Unlikely by 2030: Oral GLP-1 medications as effective as current injections Oral medications without strict dosing requirements Oral options significantly cheaper than injections The Physics Problem: Even with better technology, oral peptides face fundamental limitations: Large molecules dont easily cross intestinal barriers Digestive system will always break down some medication First-pass liver metabolism reduces bioavailability Perfect oral bioavailability is likely impossible for peptides this size Most Likely Outcome: Future oral tirzepatide will probably: Require higher doses than injectable (like Rybelsus does now) Have strict administration requirements Be less effective than injectable versions Cost similar to or more than current brand-name injectable options Serve niche population unable or unwilling to inject Should You Wait for Oral Tirzepatide
